Burkholderia thailandensis oacA mutants facilitate the expression of Burkholderia mallei-like O polysaccharides

Infection and Immunity

Volumn 79, Issue 2, 2011, Pages 961-969

  Brett, Paul J ^a   Burtnick, Mary N ^a   Heiss, Christian ^b   Azadi, Parastoo ^b   DeShazer, David ^c   Woods, Donald E ^d   Gherardini, Frank C ^e  

^a UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

^c UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^d UNIVERSITY OF CALGARY   (Canada)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; BACTERIAL POLYSACCHARIDE; BACTERIAL PROTEIN; BACTERIUM LIPOPOLYSACCHARIDE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 9C1 2; O POLYSACCHARIDE; OACA PROTEIN; UNCLASSIFIED DRUG;

ANTIBODY SPECIFICITY; ARTICLE; BURKHOLDERIA; BURKHOLDERIA MALLEI; BURKHOLDERIA THAILANDENSIS; COST EFFECTIVENESS ANALYSIS; IMMUNOBLOTTING; METHYLATION; MUTANT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OPEN READING FRAME; PHENOTYPE; PRIORITY JOURNAL; STRUCTURE ANALYSIS; WESTERN BLOTTING;

BACTERIAL PROTEINS; BURKHOLDERIA; CARBOHYDRATE CONFORMATION; GENE EXPRESSION REGULATION, BACTERIAL; MUTATION; O ANTIGENS;

EID: 79251478388     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01023-10     Document Type: Article

References (43)

1. Anuntagool, N., and S. Sirisinha. 2002. Antigenic relatedness between Burkholderia pseudomallei and Burkholderia mallei. Microbiol. Immunol. 46:143-150.
2. Bartlett, J. G. 1998. Glanders, p. 1578-1580. In S. L. Gorbach, J. G. Bartlett, and N. R. Blacklow (ed.), Infectious diseases, 2nd ed. W. B. Saunders Company, Philadelphia, PA.
3. Berry, D. S., F. Lynn, C. H. Lee, C. E. Frasch, and M. C. Bash. 2002. Effect of O acetylation of Neisseria meningitidis serogroup A capsular polysaccharide on development of functional immune responses. Infect. Immun. 70:3707-3713.
4. Bondi, S. K., and J. B. Goldberg. 2008. Strategies toward vaccines against Burkholderia mallei and Burkholderia pseudomallei. Expert Rev. Vaccines 7:1357-1365.
5. Brett, P. J., et al. 2007. Burkholderia mallei expresses a unique lipopolysaccharide mixture that is a potent activator of human Toll-like receptor 4 complexes. Mol. Microbiol. 63:379-390.
6. Brett, P. J., M. N. Burtnick, and D. E. Woods. 2003. The wbiA locus is required for the 2-O-acetylation of lipopolysaccharides expressed by Burkholderia pseudomallei and Burkholderia thailandensis. FEMS Microbiol. Lett. 218:323-328.
7. Brett, P. J., D. DeShazer, and D. E. Woods. 1998. Burkholderia thailandensis sp. nov., a Burkholderia pseudomallei-like species. Int. J. Syst. Bacteriol. 48(Pt. 1):317-320.
8. Brett, P. J., and D. E. Woods. 1996. Structural and immunological characterization of Burkholderia pseudomallei O-polysaccharide-flagellin protein conjugates. Infect. Immun. 64:2824-2828.
9. Bryan, L. E., D. Wong, D. E. Woods, D. A. Dance, and W. Chaowagul. 1994. Passive protection of diabetic rats with antisera specific for the polysaccharide portion of the lipopolysaccharide from Pseudomonas pseudomallei. Can. J. Infect. Dis. 5:170-178.
10. Burtnick, M., A. Bolton, P. Brett, D. Watanabe, and D. Woods. 2001. Identification of the acid phosphatase (acpA) gene homologues in pathogenic and non-pathogenic Burkholderia spp. facilitates TnphoA mutagenesis. Microbiology 147:111-120.
11. Burtnick, M. N., et al. 2008. Burkholderia pseudomallei type III secretion system mutants exhibit delayed vacuolar escape phenotypes in RAW 264.7 murine macrophages. Infect. Immun. 76:2991-3000.
12. Burtnick, M. N., P. J. Brett, and D. E. Woods. 2002. Molecular and physical characterization of Burkholderia mallei O antigens. J. Bacteriol. 184:849-852.
13. Burtnick, M. N., D. DeShazer, V. Nair, F. C. Gherardini, and P. J. Brett. 2010. Burkholderia mallei cluster 1 type VI secretion mutants exhibit growth and actin polymerization defects in RAW 264.7 murine macrophages. Infect. Immun. 78:88-99.
14. DeShazer, D., P. J. Brett, and D. E. Woods. 1998. The type II O-antigenic polysaccharide moiety of Burkholderia pseudomallei lipopolysaccharide is required for serum resistance and virulence. Mol. Microbiol. 30:1081-1100.
15. DeShazer, D., D. M. Waag, D. L. Fritz, and D. E. Woods. 2001. Identification of a Burkholderia mallei polysaccharide gene cluster by subtractive hybridization and demonstration that the encoded capsule is an essential virulence determinant. Microb. Pathog. 30:253-269.
16. Dubois, M., K. Gilles, J. K. Hamilton, P. A. Rebers, and F. Smith. 1956. Colorimetric method for determination of sugars and related substances. Anal. Chem. 28:350-356.
17. Fomsgaard, A., M. A. Freudenberg, and C. Galanos. 1990. Modification of the silver staining technique to detect lipopolysaccharide in polyacrylamide gels. J. Clin. Microbiol. 28:2627-2631.
18. Gregory, B. C., and D. M. Waag. 2007. Glanders, p. 121-146. In Z. F. Dembek (ed.), Medical aspects of biological warfare. Office of the Surgeon General, United States Army, Falls Church, VA.
19. Howe, C., and W. R. Miller. 1947. Human glanders: report of six cases. Ann. Intern. Med. 26:93-115.
20. Kim, H. S., et al. 2005. Bacterial genome adaptation to niches: divergence of the potential virulence genes in three Burkholderia species of different survival strategies. BMC Genomics 6:174.
21. Lopez, J., et al. 2003. Characterization of experimental equine glanders. Microbes Infect. 5:1125-1131.
22. Neubauer, H., et al. 2005. Serodiagnosis of Burkholderia mallei infections in horses: state-of-the-art and perspectives. J. Vet. Med. B Infect. Dis. Vet. Public Health 52:201-205.
23. Pearson, T., et al. 2007. VNTR analysis of selected outbreaks of Burkholderia pseudomallei in Australia. Infect. Genet. Evol. 7:416-423.
24. Perry, M. B., L. L. MacLean, T. Schollaardt, L. E. Bryan, and M. Ho. 1995. Structural characterization of the lipopolysaccharide O antigens of Burkholderia pseudomallei. Infect. Immun. 63:3348-3352.
25. Redfearn, M. S., N. J. Palleroni, and R. Y. Stanier. 1966. A comparative study of Pseudomonas pseudomallei and Bacillus mallei. J. Gen. Microbiol. 43:293-313.
26. Reeves, P. 1995. Role of O-antigen variation in the immune response. Trends Microbiol. 3:381-386.
27. Rotz, L. D., A. S. Khan, S. R. Lillibridge, S. M. Ostroff, and J. M. Hughes. 2002. Public health assessment of potential biological terrorism agents. Emerg. Infect. Dis. 8:225-230.
28. Sarkar-Tyson, M., and R. W. Titball. 2010. Progress toward development of vaccines against melioidosis: a review. Clin. Ther. 32:1437-1445.
29. Schell, M. A., et al. 2007. Type VI secretion is a major virulence determinant in Burkholderia mallei. Mol. Microbiol. 64:1466-1485.
30. Schweizer, H., T. Klassen, and T. Hoang. 1996. Improved methods for gene analysis and expression in Pseudomonas spp. In T. Nakazawa, K. Furukawa, D. Haas, and S. Silver (ed.), Molecular biology of pseudomonads. American Society for Microbiology, Washington, DC.
31. Shanks, J., et al. 2009. Burkholderia mallei tssM encodes a putative deubiquitinase that is secreted and expressed inside infected RAW 264.7 murine macrophages. Infect. Immun. 77:1636-1648.
32. Slauch, J. M., A. A. Lee, M. J. Mahan, and J. J. Mekalanos. 1996. Molecular characterization of the oafA locus responsible for acetylation of Salmonella typhimurium O-antigen: oafA is a member of a family of integral membrane trans-acylases. J. Bacteriol. 178:5904-5909.
33. Slauch, J. M., M. J. Mahan, P. Michetti, M. R. Neutra, and J. J. Mekalanos. 1995. Acetylation (O-factor 5) affects the structural and immunological properties of Salmonella typhimurium lipopolysaccharide O antigen. Infect. Immun. 63:437-441.
34. Song, H., et al. 2010. The early stage of bacterial genome-reductive evolution in the host. PLoS Pathog. 6:e1000922.
35. Srinivasan, A., et al. 2001. Glanders in a military research microbiologist. N. Engl. J. Med. 345:256-258.
36. Stanton, A. T., and W. Fletcher. 1925. Meliodosis, a disease of rodents communicable to man. Lancet i:10-13.
37. Trevino, S. R., et al. 2006. Monoclonal antibodies passively protect BALB/c mice against Burkholderia mallei aerosol challenge. Infect. Immun. 74:1958-1961.
38. Ulrich, R. L., and D. DeShazer. 2004. Type III secretion: a virulence factor delivery system essential for the pathogenicity of Burkholderia mallei. Infect. Immun. 72:1150-1154.
39. Ulrich, R. L., D. Deshazer, H. B. Hines, and J. A. Jeddeloh. 2004. Quorum sensing: a transcriptional regulatory system involved in the pathogenicity of Burkholderia mallei. Infect. Immun. 72:6589-6596.
40. Voskuhl, G. W., P. Cornea, M. S. Bronze, and R. A. Greenfield. 2003. Other bacterial diseases as a potential consequence of bioterrorism: Q fever, brucellosis, glanders, and melioidosis. J. Okla. State Med. Assoc. 96:214-217.
41. Wilkinson, L. 1981. Glanders: medicine and veterinary medicine in common pursuit of a contagious disease. Med. Hist. 25:363-384.
42. Woods, D. E., J. A. Jeddeloh, D. L. Fritz, and D. DeShazer. 2002. Burkholderia thailandensis E125 harbors a temperate bacteriophage specific for Burkholderia mallei. J. Bacteriol. 184:4003-4017.
43. Yabuuchi, E., et al. 1992. Proposal of Burkholderia gen. nov. and transfer of seven species of the genus Pseudomonas homology group II to the new genus, with the type species Burkholderia cepacia (Palleroni and Holmes 1981) comb. nov. Microbiol. Immunol. 36:1251-1275.